Monte Rosa Therapeutics, Inc. (GLUE) Stock Analysis

Q: What is the GLUE stock price target?

Take-profit $28.13 (+56.2% upside). Prior stop was $17.14.

Q: Is GLUE overvalued or undervalued?

Monte Rosa Therapeutics, Inc. trades at a P/E of N/A (forward -9.9). TrendMatrix value score: 5.4/10. Overall verdict: Sell.

Q: What do analysts say about GLUE?

15 analysts cover GLUE with a consensus score of 4.3/5. Average price target: $32.

SellModerate ConfidenceUpdated 1 days ago (May 19, 2026, 6:21 AM ET)

Healthcare · Biotechnology

$18.01+56.2% A.UpsideScore 4.1/10#149 of 157 Biotechnology

QualityF-score2 / 9FCF yield-5.07%

Stop $17.14Target $28.13(analyst − 13%)A.R:R 5.0:1

Analyst target$32.33+79.5%6 analysts

$28.13our TP

$18.01price

$32.33mean

$37

Sell if holding. Engine safety override at $18.01: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 5.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.1/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Monte Rosa Therapeutics, Inc.

Latest news

JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $31 — benzinga May 11, 2026 positive
Monte Rosa Therapeutics Q1 EPS $(0.45) Misses $(0.37) Estimate, Sales $4.210M Miss $10.883M Estimate — benzinga May 7, 2026 negative
10 Health Care Stocks Whale Activity In Today's Session — benzinga May 6, 2026 neutral
Monte Rosa To Present Preclinical Data Highlighting Potential Of CCNE1-Directed MGD, MRT-55811, To Treat CCNE1-Amplified — benzinga Apr 20, 2026 positive

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (1.4 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-9.9

Mkt Cap$1.5B

EV/EBITDA-6.4

Profit Mgn0.0%

ROE-32.6%

Rev Growth-95.0%

Beta1.62

DividendNone

Rating analysts15

Quality Signals

Piotroski F2/9

Options Flow

P/C0.73neutral

IV90%elevated

Max Pain$15-16.7% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

5 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.415%0.81

Quality1.415%0.21

Growth5.015%0.75

Momentum3.010%0.30

Sentiment7.610%0.76

Insider Activity3.910%0.39

Peer Rank1.810%0.18

Technical Setup7.55%0.38

Risk Profile2.25%0.11

Catalyst3.55%0.18

Overall (Σ contributions)4.06

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

2.2

Moat

2.5

Current Ratio

5.0

Cash-burning: FCF -180% of revenueNo competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

0.3

Value Rank

1.3

Quality Rank

4.7

Volatile — 5.6% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover

0.0

Volatility

0.0

Implied Vol

0.0

Debt Equity

0.0

Short Interest

1.7

Max Pain Risk

3.0

Beta

4.6

Put Call

8.5

High short interest justified: 18%High IV: 90%Above max pain $15

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Obv

1.0

Volume

2.5

Rsi

5.5

Ma Position

6.0

Volume distribution (falling OBV)Above 200-day MA

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg

0.5

Earnings History

3.3

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 2B/2M

GatesMomentum 3.0<4.5A.R:R 5.0 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

43 · Neutral

↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $17.67Resistance $21.62

Price Targets

$17

$28

A.Upside+56.2%

A.R:R5.0:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.4 < 4.0)

! Momentum score 3.0/10 — below 4.5 minimum

Earnings

2/4 beats

Next Earnings2026-08-06 (79d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is GLUE stock a buy right now?

Sell if holding. Engine safety override at $18.01: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 5.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $17.14. Score 4.1/10, moderate confidence.

What is the GLUE stock price target?

Take-profit target: $28.13 (+56.2% upside). Prior stop was $17.14. Stop-loss: $17.14.

What are the risks of investing in GLUE?

Quality below floor (1.4 < 4.0).

Is GLUE overvalued or undervalued?

Monte Rosa Therapeutics, Inc. trades at a P/E of N/A (forward -9.9). TrendMatrix value score: 5.4/10. Verdict: Sell.

What do analysts say about GLUE?

15 analysts cover GLUE with a consensus score of 4.3/5. Average price target: $32.

What does Monte Rosa Therapeutics, Inc. do?Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small...

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.